Explore
Validate
LearnNB100-56618
antibody from Novus Biologicals
Targeting: TNFRSF10B
CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [39]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB100-56618 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB100-56618, RRID:AB_838158
- Product name
- Rabbit Polyclonal TRAILR2/TNFRSF10B Antibody
- Antibody type
- Polyclonal
- Description
- Protein G purified.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 mg
- Concentration
- 1.0 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response.
First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling.
H-Ras regulation of TRAIL death receptor mediated apoptosis.
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy.
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways.
TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
Sp1-mediated TRAIL induction in chemosensitization.
Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy.
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.
Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9.
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis.
The transcriptosomal response of human A549 lung cells to a hydrogen peroxide-generating system: relationship to DNA damage, cell cycle arrest, and caspase activation.
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein.
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Shin GC, Kang HS, Lee AR, Kim KH
Autophagy 2016 Dec;12(12):2451-2466
Autophagy 2016 Dec;12(12):2451-2466
First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
Allen JE, Crowder RN, El-Deiry WS
PloS one 2015;10(11):e0143082
PloS one 2015;10(11):e0143082
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 1;21(23):5338-48
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 1;21(23):5338-48
NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Foster KA, Jane EP, Premkumar DR, Morales A, Pollack IF
International journal of oncology 2015 Aug;47(2):506-16
International journal of oncology 2015 Aug;47(2):506-16
ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
Talekar MK, Allen JE, Dicker DT, El-Deiry WS
Cell cycle (Georgetown, Tex.) 2015 Aug 3;14(15):2422-8
Cell cycle (Georgetown, Tex.) 2015 Aug 3;14(15):2422-8
Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV, Allen JE, Dicker DT, El-Deiry WS
Cancer research 2015 Apr 1;75(7):1423-32
Cancer research 2015 Apr 1;75(7):1423-32
The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling.
Xu J, Zhou JY, Xu Z, Kho DH, Zhuang Z, Raz A, Wu GS
Cell cycle (Georgetown, Tex.) 2014;13(23):3750-8
Cell cycle (Georgetown, Tex.) 2014;13(23):3750-8
H-Ras regulation of TRAIL death receptor mediated apoptosis.
Chen JJ, Bozza WP, Di X, Zhang Y, Hallett W, Zhang B
Oncotarget 2014 Jul 15;5(13):5125-37
Oncotarget 2014 Jul 15;5(13):5125-37
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS
PloS one 2013;8(9):e75414
PloS one 2013;8(9):e75414
Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
Di X, Zhang G, Zhang Y, Takeda K, Rivera Rosado LA, Zhang B
Oncotarget 2013 Sep;4(9):1349-64
Oncotarget 2013 Sep;4(9):1349-64
Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
Xu J, Xu Z, Zhou JY, Zhuang Z, Wang E, Boerner J, Wu GS
The Journal of biological chemistry 2013 Nov 15;288(46):33263-71
The Journal of biological chemistry 2013 Nov 15;288(46):33263-71
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy.
Qiu F, Hu M, Tang B, Liu X, Zhuang H, Yang J, Hua ZC
Scientific reports 2013 Dec 20;3:3565
Scientific reports 2013 Dec 20;3:3565
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.
Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS
Molecular cancer therapeutics 2012 Oct;11(10):2087-95
Molecular cancer therapeutics 2012 Oct;11(10):2087-95
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP, Premkumar DR, Pollack IF
Molecular cancer therapeutics 2011 Jan;10(1):198-208
Molecular cancer therapeutics 2011 Jan;10(1):198-208
Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways.
Zhang X, Chen W, De Paiva CS, Corrales RM, Volpe EA, McClellan AJ, Farley WJ, Li DQ, Pflugfelder SC
Investigative ophthalmology & visual science 2011 Aug 9;52(9):6279-85
Investigative ophthalmology & visual science 2011 Aug 9;52(9):6279-85
TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, Hazle JD, Lev D
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 1;16(9):2591-604
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 1;16(9):2591-604
Sp1-mediated TRAIL induction in chemosensitization.
Xu J, Zhou JY, Wei WZ, Philipsen S, Wu GS
Cancer research 2008 Aug 15;68(16):6718-26
Cancer research 2008 Aug 15;68(16):6718-26
Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki K, Eguchi K
Journal of hepatology 2007 Oct;47(4):546-55
Journal of hepatology 2007 Oct;47(4):546-55
Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy.
Xu J, Zhou JY, Wu GS
Cancer research 2006 Oct 15;66(20):10092-9
Cancer research 2006 Oct 15;66(20):10092-9
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Younes M, Georgakis GV, Rahmani M, Beer D, Younes A
European journal of cancer (Oxford, England : 1990) 2006 Mar;42(4):542-7
European journal of cancer (Oxford, England : 1990) 2006 Mar;42(4):542-7
Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Song JH, Bellail A, Tse MC, Yong VW, Hao C
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 Mar 22;26(12):3299-308
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 Mar 22;26(12):3299-308
3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.
Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S
Carcinogenesis 2006 Apr;27(4):717-28
Carcinogenesis 2006 Apr;27(4):717-28
Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL, Zou WY, Song LH, Wei W
Cancer chemotherapy and pharmacology 2005 Feb;55(2):189-96
Cancer chemotherapy and pharmacology 2005 Feb;55(2):189-96
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A
British journal of haematology 2005 Aug;130(4):501-10
British journal of haematology 2005 Aug;130(4):501-10
c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY
Cancer research 2004 Oct 15;64(20):7570-8
Cancer research 2004 Oct 15;64(20):7570-8
Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9.
Kim K, Nakagawa H, Fei P, Rustgi AK, El-Deiry WS
Cell death and differentiation 2004 May;11(5):583-7
Cell death and differentiation 2004 May;11(5):583-7
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis.
Jin Z, McDonald ER 3rd, Dicker DT, El-Deiry WS
The Journal of biological chemistry 2004 Aug 20;279(34):35829-39
The Journal of biological chemistry 2004 Aug 20;279(34):35829-39
The transcriptosomal response of human A549 lung cells to a hydrogen peroxide-generating system: relationship to DNA damage, cell cycle arrest, and caspase activation.
Dandrea T, Hellmold H, Jonsson C, Zhivotovsky B, Hofer T, Wärngård L, Cotgreave I
Free radical biology & medicine 2004 Apr 1;36(7):881-96
Free radical biology & medicine 2004 Apr 1;36(7):881-96
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Koyama S
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Koyama S
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK
Cancer research 2003 Apr 1;63(7):1712-21
Cancer research 2003 Apr 1;63(7):1712-21
Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Zhang HG, Xie J, Xu L, Yang P, Xu X, Sun S, Wang Y, Curiel DT, Hsu HC, Mountz JD
Journal of virology 2002 Jun;76(11):5692-700
Journal of virology 2002 Jun;76(11):5692-700
Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Zhang HG, Xie J, Xu L, Yang P, Xu X, Sun S, Wang Y, Curiel DT, Hsu HC, Mountz JD
Journal of virology 2002 Jun;76(11):5692-700
Journal of virology 2002 Jun;76(11):5692-700
Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S, Koike N, Adachi S
Journal of cancer research and clinical oncology 2002 Feb;128(2):73-9
Journal of cancer research and clinical oncology 2002 Feb;128(2):73-9
Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
Eid MA, Lewis RW, Kumar MV
Molecular cancer therapeutics 2002 Aug;1(10):831-40
Molecular cancer therapeutics 2002 Aug;1(10):831-40
The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein.
Basile JR, Zacny V, Münger K
The Journal of biological chemistry 2001 Jun 22;276(25):22522-8
The Journal of biological chemistry 2001 Jun 22;276(25):22522-8
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S
Cancer research 2001 Jun 15;61(12):4892-900
Cancer research 2001 Jun 15;61(12):4892-900
Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Burns TF, Bernhard EJ, El-Deiry WS
Oncogene 2001 Aug 2;20(34):4601-12
Oncogene 2001 Aug 2;20(34):4601-12
Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K, Fisher MJ, Xu SQ, el-Deiry WS
Clinical cancer research : an official journal of the American Association for Cancer Research 2000 Feb;6(2):335-46
Clinical cancer research : an official journal of the American Association for Cancer Research 2000 Feb;6(2):335-46
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Total protein from HL-60, HepG2, HCT-116 and human placenta was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TRAIL R2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis using the Azide Free version of NB100-56618. Detection of 20 ug of whole cell lysates from HL60 cells with anti-TRAIL-R2 at 5 ug/ml.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis of a formalin fixed paraffin-embedded (FFPE) human brain cerebellum using 1:200 conc. of TRAIL R2/TNFRSF10B antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 30 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 9.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 15 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Cytoplasmic staining was observed in the Purkinje cell layer.
